Harmony Biosciences On Sept 28, Received Notice From Novugen Pharma & Lupin Seeking Approval To Manufacture, Sell A Generic Version Of Wakix In U.S.
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences has received a notice from Novugen Pharma and Lupin, seeking approval to manufacture and sell a generic version of Wakix in the U.S. This information was disclosed in a SEC 8K filing.
October 04, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harmony Biosciences could face competition if Novugen Pharma and Lupin receive approval to manufacture and sell a generic version of Wakix.
The introduction of a generic version of Wakix could potentially reduce Harmony Biosciences' market share and revenues, negatively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100